Impact of Oral Phosphorus Supplements on the 6-month Change in FGF23 Levels in Anorexic Adolescents Suffering From Undernutrition.

Last updated: May 27, 2026
Sponsor: Centre Hospitalier Universitaire, Amiens
Overall Status: Completed

Phase

N/A

Condition

Anorexia

Diet And Nutrition

Weight Loss

Treatment

N/A

Clinical Study ID

NCT02812134
PI2015_843_0006
  • Ages 11-17
  • All Genders

Study Summary

Fibroblast growth factor 23 (FGF23) is a recently discovered phosphaturic hormone produced by osteocytes. It is involved in phosphate-calcium metabolism (via its phosphaturic action and inhibition of 1,25-OH vitamin D).

There are no published studies on the role of FGF23 in undernourished anorexic adolescents taking oral phosphorus supplements.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Adolescents aged from 11 to 17

  • Follow-up or hospitalisation for anorexia

  • Overt undernutrition (clinical signs of undernutrition, body mass index and theWaterlow index)

  • Social security coverage

Exclusion

Exclusion Criteria:

  • Known pre-existing renal disorders

  • Known constitutional disorders of phosphate-calcium metabolism

  • Adult patients, legal guardianship, incarceration

Study Design

Total Participants: 30
Study Start date:
March 26, 2016
Estimated Completion Date:
June 16, 2017

Connect with a study center

  • CHU Amiens

    Amiens, 80054
    France

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.